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2 These authors contributed equally in this study.Engineering of fetal tissue has a high potential for the treatment of acute and chronic wounds of the skin
in humans as these cells have high expansion capacity under simple culture conditions and one organ
donation can produce Master Cell Banks which can fabricate over 900 million biological bandages
(9  12 cm). In a Phase 1 clinical safety study, cases are presented for the treatment of therapy resistant
leg ulcers. All eight patients, representing 13 ulcers, tolerated multiple treatments with fetal biological
bandages showing no negative secondary effects and repair processes similar to that seen in 3rd degree
burns. Differential gene proﬁling using Affymetrix gene chips (analyzing 12,500 genes) were accom-
plished on these banked fetal dermal skin cells compared to banked dermal skin cells of an aged donor
in order to point to potential indicators of wound healing. Families of genes involved in cell adhesion and
extracellular matrix, cell cycle, cellular signaling, development and immune response show signiﬁcant
differences in regulation between banked fetal and those from banked old skin cells: with approximately
47.0% of genes over-expressed in fetal ﬁbroblasts. It is perhaps these differences which contribute to efﬁ-
cient tissue repair seen in the clinic with fetal cell therapy.
 2008 Elsevier Inc. All rights reserved.1. Introduction health concern. Patient’s suffering has long been underestimatedConsiderable interest and research has been dedicated to the
understanding of wound healing and the associated process.
Whereas adult cutaneous wounds heal more slowly and with scar
formation to restore tissue integrity, fetal skin, in utero, is observed
to have rapid and scar-less tissue repair characterized by regener-
ation of an organized dermis with normal appendages and by a rel-
ative lack of inﬂammation. (Beanes et al., 2002; Bullard et al., 2003;
Cass et al., 1997; Adzick and Lorenz, 1994; Armstrong and Fergu-
son, 1995; Dang et al., 2003; Lorenz et al., 1995). Fundamental dif-
ferences between fetal and adult skin and the fetal and adult skin
wound environment may be important in inducing efﬁcient tissue
repair. Chronic wounds, more speciﬁcally leg ulcers, are a majorll rights reserved.
f Musculoskeletal Medicine,
03, Rm. 121, 1011 Lausanne,
8414.
.A. Applegate).
University Hospital, Lausanne.and recent evaluations of quality-of-life reveal that patients with
leg ulcers have complaints that are substantial and similar to those
previously reported for patients with chronic obstructive pulmon-
ary disease, osteoarthritis or angina (Kahn et al., 2004). Costs are
considerable and were calculated to exceed 0.5 billion euros/year
in Germany and the direct cost of leg ulcers in the UK were calcu-
lated at 400 million euros a year (Hafner et al., 1999). Similarly in
the United States, estimations are as high as 3 billion dollars for
treatment of all forms of leg ulcers. Important variables for cost dif-
ferences between countries are the frequency of bandage changes
and duration of time for each bandage change (Ragnarson and
Hjelmgren, 2005). Etiological treatment of venous ulcers is manda-
tory in order to prevent relapse. Compression therapy is the cor-
nerstone of venous ulcer treatment and high rates of healing (up
to 83% in 6 months) may be obtained by different techniques (Boo-
za et al., 2005). However, such results are not obtained by all
teams, and considerable biases of recruitment do exist. In countries
with a high standard of health care and a good prevention of ve-
nous insufﬁciency, resistant ulcers are more and more frequent
and present as a difﬁcult therapeutic challenge (Chaby et al.,
2006; Marklund et al, 2000).
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wound dressings. However, there is no evidence in the literature
that their use really improves the healing rate of venous ulcers
(Booza et al., 2005). Therefore, there is an urgent need for new
techniques in the treatment of refractory leg ulcers.
New biological therapies for wound healing have signiﬁcantly
advanced including growth factors, skin substitutes, gene and
stem cell therapies as well as tissue engineering. The origin of
cell choice, their interaction with a biomaterial and the simplic-
ity of preparation is extremely important for eventual therapeu-
tic usage.
Autologous skin ﬁbroblasts and substitutes of various nature
have been used on leg ulcers to date (Limat et al., 1996; Uccioli,
2003; Caravaggi et al., 2003; Cavallini, 2007) with different degrees
of efﬁciency. Major drawbacks are that production time is long
since patient tissues are necessary for processing. Allogenic skin
substitutes using foreskin tissue (Dermagraft, Apligraf and Or-
cel) have shown decreased healing times for diabetic foot ulcers,
other ulcers and non-weight bearing wounds (Falanga et al., 1998;
Marston et al., 2003). The production time is long and we have re-
cently shown high differences in gene expression of banked fetal
and foreskin cells used in tissue engineering (Hirt-Burri et al.,
2008) which could be, in part, responsible for differences of efﬁ-
ciency seen in the clinic to date.
As banked fetal skin ﬁbroblasts have been previously shown to
efﬁciently induce tissue repair in burns and in acute wounds
(Hohlfeld et al., 2005; de Buys Roessingh et al., 2006; Quintin
et al., 2007), it was of interest to look at the effect on recalcitrant
leg ulcers with different etiologies in the elderly to see if a full clin-
ical trial would be of merit. In this Phase I safety clinical study, we
particularly wanted to evaluate the tolerance of multiple treat-
ments with fetal cell biological bandages and interaction with
the chronic wound environment. With these speciﬁcally banked fe-
tal skin cells used in tissue engineering, we performed microarray
analysis to identify differences on the molecular level between
speciﬁc gene clusters compared to old skin cells, banked in the
same manner, which could give some insight into signiﬁcant
parameters involved in efﬁcient wound healing.
2. Materials and methods
2.1. Skin donations and cell bank synthesis
Cell lines established in theUniversity Hospital of Lausanne from
a fetal skin biopsy at 14 weeks of gestation (14 week male fetal
skin;14 wFS) obtained after pregnancy termination with informed
andwritten consent and approval fromthe localMedical School Eth-
ics Committee. Normal skin from an old male donor (75 yr old skin;
75 yOS) was obtained in the Department of Dermatology in the Uni-
versity Hospital of Lausanne from a non-sun-exposed skin site (but-
tocks) also with informed consent and approval from the Medical
School Ethics Committee.
From 1 cm2 skin biopsies, three individual cultures were estab-
lished from each of the biopsies of 14 wFS and 75 yOS to prepare
cell banks including all of the vials of cells necessary for the micro-
array analysis at passage 3 for each of the 6 cell banks (fetal and
aged skin cell banks). Dermal tissue was dissected into <0.5 mm3
fragments and grown in DMEM supplemented with 10% FCS and
glutamine and the cells were used for experimentation at passage
3. They were grown to conﬂuence before splitting and rinsed twice
with PBS and counted.
The detailed procedure has been described previously (de Buys
Roessingh et al., 2006) and speciﬁc conditions for the study herein
are described brieﬂy. The tissue was divided into three, 10 cm
plates with whole tissue fragments 10 per plate (<0.5 mm3). Tis-sue culture dishes were previously scored deeply with a sterile
scalpel in a check-board pattern under the laminar ﬂow hood. Tis-
sue fragments were placed into the scored plastic regions mincing
gently. A small quantity of nutrient media was placed around each
fragment to avoid ﬂoating of tissues for the ﬁrst 24 h. Rare ﬂoating
tissues could be overlaid with a sterile microscope cover slide for
the ﬁrst 24 h if necessary. Following the ﬁrst 24 h, 8 ml of culture
media was added onto each 10 cm plate and this was changed
two times per week before passage. These fragments were grown
in DMEM supplemented with only 10% fetal bovine serum (Hy-
clone) to help insure a consistent dermal skin cell culture. Cell cul-
tures were grown at 37 C in a humidiﬁed atmosphere of 95% air/
10% CO2. It is important to mention that any nutrient component
necessary for cell culture for clinical trials should have thorough
safety requirements and tracing. All animal derived products, such
as for fetal bovine serum and trypsin, speciﬁc clinical lots of trypsin
and gamma irradiated serum that have been tested for adventi-
tious agents should be employed (Quintin et al., 2007).
When cell growth advanced after approximately 1 week for
fetal tissues and 2 weeks for adult, dishes of tissue and cells
were trypsinized (0.25% trypsin-0.1% ethylene diaminetetraacetic
acid [EDTA]). At this point 20 plates were frozen into individual
units in liquid nitrogen for each of the three tissue cultures. Cells
were centrifuged at 2000g for 15 min and resuspended in a
freezing solution of DMEM (5 ml) + FCS (4 ml) + DMSO (1 ml, Flu-
ka) and frozen in 1 ml aliquots (5 million cells) at –80 C in
Nalgene Cryo 1 C Freezing Container’s (Nalgene) to achieve a
1 C/min rate of cooling and freezing curve. After 24 h, cells
were transferred to liquid nitrogen for longer storage. Three
independent cell banks for each biopsy of 14 wFS and 75 yOS
were prepared (denominated FCB and OCB hereafter for Fetal
Cell Bank and Old Cell Bank). We have seen that cells frozen
in this manner are capable of being stored for at least 15 years
in our laboratory.
2.1.1. Ethical aspects of working with human fetal cells
Although there is a high medical support for developing cellular
based therapies to reach as many patients as possible, there exists
a governing political controversy. Scientists and medical doctors
have used fetal tissue since the 1930’s as a means to understand
cell biology and as an essential tool in the development of vaccines.
The 1954 Nobel Prize for Medicine was awarded to immunologists
who developed the polio vaccine using cultures of human fetal kid-
ney cells. The drastic change in the political environment changed
in 1988 when scientists began using fresh fetal tissue and cells for
transplantation into patients with Parkinson’s disease. Unfortu-
nately, the Reagan administration (US government) declared a
moratorium on all federal funding for fetal tissue research. Ad-
vances for fetal cell research were then left only to the ‘‘private sec-
tor” where there is no medical peer-review of adapted therapies.
Indeed, if research on whole-cell bio-processing of many fetal tis-
sues could have continued, there certainly would have been ad-
vances in the amount of tissue necessary for developing efﬁcient
therapies (such as with fetal skin where only one organ donation
is necessary to allow for cellular expansion to develop over 900
million fetal skin constructs). In Switzerland and most countries,
the fetal skin is considered as an organ donation by law. This pro-
cess is highly regulated including federal approval for tissue
biopsy, stocking and transplantation and ethics committee ap-
proval of the procedure and all information for the donor. Even
though termination of pregnancy is legally allowed, there will al-
ways be strong opponents which will interfere that the laws and
practices can remain patient centered (conditions which permit
to end an unwanted pregnancy in the best possible way and with-
out unnecessary suffering).
Table 1
Primers for real time conﬁrmation.
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Preliminary experiments investigating cell seeding density
(from 102 to 105 cells cm2) and growth periods (from 1 to 6 days)
on a 9  12 cm equine collagen sheet of 2 mm thickness dry weight
(TissueFleece, Baxter, Switzerland) were performed in order to
determine optimal conditions for fetal skin construct preparation.
Fetal cells at passages 3 or 4 were placed in 20 ml media (DMEM
containing 10% FBS) and seeded on the collagen sheet by making
small incisions at 2 cm intervals into the collagen matrix with a
sterile, small bored Pasteur pipette. The sheet containing the fetal
dermal cells (denominated as fetal skin construct) was placed into
a 37 C incubator at 95% relative humidity and 10% CO2. An addi-
tional 30 ml media was added 1 h later. Fetal skin cell constructs
remained at a 2 mm thickness as the original dry collagen sheets.
A seeding density of 5  103 cells/cm2 with cells in passages 3–4
and a growth period of 3 days were employed for the patients in
this study.
2.3. Patient selection, preparation and treatment regimen
Patients were selected on the basis of a history of having refrac-
tory chronic leg ulcers, which did not heal using traditional thera-
pies, such as compression (active and passive), hydrocolloids, auto-
grafts, among others. A total of 9 patients were admitted in the
study including 13 ulcers total (Average age = 73 Yr, 4 males and
5 females). Patients recruited suffered from refractory venous ul-
cers including ulcers with atrophie blanche. In four of these pa-
tients, it was possible to accomplish a thorough investigation,
including venous (duplex) and arterial investigations (ABI and du-
plex). Characteristics of patients are presented in the next section.
At each visit, the chronic ulcers were cleaned with physiological
saline. Fibrin and necrotic tissue was removed with a curette. Then,
the fetal skin construct was applied to cover the entire wound sur-
face, followed by a gauze impregnated with Vaseline, and, if not
contra-indicated (one patient suffered from arterio-venous ulcer),
compression therapy with long stretch bandage. Application of
constructs was one time a week, followed to 4 days to bandage
change. Bandages were then changed every two days (Vaseline
gauze). There was no modiﬁcation of medication, way of living,
or compression bandaging throughout the fetal skin construct
application.
2.4. Analysis of gene expression
Gene expression for approximately 12,500 probes representing
known genes and expressed sequence tag (EST) proﬁling of cul-
tured fetal and old human primary ﬁbroblasts was analyzed.
The RNA was isolated from cultured cells at passage 1 for each
of the three cell banks for 14 wFS and 75 yOS using the NucleoSpin,
RNA II kit (Marchery-Nagel, Düren, Germany) as described by the
manufacturer. The RNA samples were monitored with the Agilent
2100 Bioanalyser, consistently demonstrating high-quality RNA
(28S/18S ratio approximately 2, but always less than 3). Total
RNA (7 lg) was converted to biotinylated cRNA as previously de-
scribed (Mutch et al., 2002), and then hybridized to the Affymetrix
human genome U95A chip (Affymetrix UK, High Wycombe) con-
taining about 12,500 probes. The comparison was performed in
triplicate with three cell banks established independently from
the same biopsies (14 wFS and 75 yOS).
2.5. Data analysis
The statistical analyses were performed as reported by Mansou-
rian et al., 2004 with a classical analysis of variance (ANOVA) fol-
lowed by The Global Error Assessment (GEA). In short, The GEAapproach takes advantage of several inherent characteristics of
microarrays that results in a robust estimate of the error and in a
slightly increased statistical power. The method is based on the
assumption that any observed difference between the error of
genes similarly expressed is only due to sampling. Therefore, after
estimating from an ANOVA the mean square error (MSE) of each
probe on the microarray independently, in a second step, a robust
MSE is calculated from average MSE of 200 neighboring genes with
similar intensity signals. In a third step, a new F statistic is recalcu-
lated replacing the MSE of the current gene with the robust MSE
with the appropriate number of degrees of freedom (df). Averaging
the MSE results in a more robust statistic and the increased num-
ber of df results into a slightly increased power. Genes were se-
lected by this method at a level 0.001. Signiﬁcant genes, with at
least a 1.5-fold change log2, were classiﬁed according to the gene
ontology following the criteria of the DAVID (database for annota-
tion, visualization, and integrated discovery) (Dennis et al., 2003).
This gene list was subjected to the KEGG database (www.geno-
me.jp/Kegg/tool/colorpathway) for signaling pathways.
2.6. Reverse transcription and real time–PCR (RT–PCR)
The results obtained with the Affymetrix Human GeneChip
were conﬁrmed by RT-PCR for 12 genes using the same fetal and
old ﬁbroblast cell lines.
One microgram of total RNA was reverse transcribed using the
StratScript reverse transcriptase enzyme (Stratagene, San Diego,
CA) as described by the manufacturer. The thermocycler Biometra
T-1 (Bimedicinisch Analytic GmbH, Göttingen) was programmed as
follows: 25 C 10 min, 37 C 60 min and 90 C 5 min.
Real time PCR using 160 ng of cDNA were performed with ABI
Prism 7000 Sequence Detection System (Applied Biosystem, Foster
City, CA). We measure the gene expression of 10 genes using Taq-
Man Gene Expression Assays (Applied Biosytems) (Table 1). Mea-
surements were performed in triplicates and results are presented
associated with standard deviation of the mean. Relative gene
expressions was expressed as -DDCT (log2) analyzed with the
2DDCT method by Livak and Schmittgen (2001) and normalized
to actin gene.
3. Results
3.1. Preliminary assessment of fetal skin constructs on chronic wounds
In a total of 9 patients treated with fetal cell therapy from 3 to
31 weeks concerning 13 ulcers, we were able to see 8 ulcers closed
completely, 4 with signiﬁcant amelioration in size but not com-
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tients estimated that there was a substantial improvement. We
present the detail of 4 patients herein as we have completed data
including venous (Duplex) and arterial investigations (ABI and du-
plex) described according to CEAP classiﬁcation (Eklöf et al., 2004).
3.1.1. Patient 1
EF is a very compliant 64 years old female patient, with a his-
tory of painful post-thrombotic ulcer for 10 years, consecutive to
deep venous system and short saphenous vein insufﬁciency (CEAP
C2,3,4b,6S ES AS2,3,4 D13,14 PR) (Fig. 1, Ulcer 1). Previous auto-grafts and
different compression therapies including four layers bandages
were of no success.
Immediately following the ﬁrst fetal skin construct, edema
diminished, pain was relieved, and ﬁbrin production elimination
was evident. This large, deep and painful ulcer healed rapidly with
applications of fetal skin constructs one time per week. At 11
weeks, the larger portion of the ulcer was healed. At one year fol-Fig. 1. Ulcers treated with fetal skin constructs one time per week for Patient 1, illustratin
two separate ulcers (Ulcer 1 and Ulcer 2).low-up, patient shows skin that is still atrophic but no presence of
scar tissue (Fig. 1, Ulcer 1). A new ulcer presented at the ankle one
year later and was also successfully closed rapidly without scar
(Fig. 1, Ulcer 2).
3.1.2. Patient 2
LG is a 62 years old female patient presenting with post-throm-
botic bilateral lipodermatosclerosis and atrophie blanche on the
lower legs, with an atypical ulcer on the lateral right lower leg
since 20 months (CEAP C4b,6 s, ES, AS1,2,3, D13,14, P18,PR) (Fig. 2, Patient
2).
Following fetal cell therapy, the edema and itching immediately
disappeared and the original ulcer closed gradually. Because of the
fragility of the skin, even though the ulcer of origin was closed a
new ulceration occurred at distance from the previous one. For bet-
ter wound preparation, this patient had the vacuum assisted device
(VAC) applied for one week with the intention of applying an auto-
graft. The ulcer and associated minor ulcerations then rapidlyg the evolution at 1, 3, 6 and 9 months and follow-up at 15 or 30 months for each of
Fig. 2. Patients 2, 3 and 4 at the beginning of fetal skin construct treatment which was applied one time per week. Evolution at 2 w and 1 month for Patient 2 and 3 mo and
one year are shown for Patient 3. Patient 4 was treated 3 times with fetal skin constructs to prepare wound bed for auto-graft treatment. These patients show the diversity of
sensitivity of the recalcitrant ulcers treated. Fibrous tissue removal remained pivotal for treatment regimen.
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which is quite an unusual favorable evolution. Atrophie blanche
was stable and no new ulceration developed at the one year fol-
low-up.
3.1.3. Patient 3
CC is a 37 years old female patient, suffering since 10 years with
a severe post-traumatic post-thrombotic syndrome, with atrophie
blanche (Fig. 2, Patient 3). A painful therapy resistant medial mal-
leolar venous leg ulcer developed 2 years ago, consecutive to ve-
nous reﬂux in the deep and superﬁcial venous systems, and leg
perforators (CEAP C3,4b,6S ES AS 2,3,4 D 13,14,15 P 18 PR), aggravated
by an arthrodesis of the ankle. Local treatment with fetal cell ther-
apy achieved rapid healing and relieving of pain. However, repeti-
tive inﬂammatory outbreaks of atrophie blanche in spite of fetal cell
treatment or tacrolimus ointment, new superﬁcial post-traumatic
ulcerations developed and healed intermittently.
3.1.4. Patient 4
RG is an 85 year old male patient suffering global heart failure
and severe bilateral knee arthritis presenting with bilateral large
ankle ulcers with mild edema and pain over the last 10 years. Vas-
cular investigations were not performed in this case (CEAP C3,6 S
ENANPN) (Fig. 2, Patient 4).
Previous auto-grafts associated to lymphatic drainage and com-
pression therapy allowed temporary wound closure, but recur-
rence appeared after only a few months each time. Following
fetal skin construct application used to prepare the wound bed
and to eliminate high ﬁbrin content, auto-grafts were performed
on the ulcer site.
Rapidly, wounds healed after one auto-graft application
whereas in previous treatments, multiple auto-grafts were neces-
sary for closure with this patient. The wound site was stable duringthe last two years of the patient’s life which was a long period for
no recurring ulcers compared to previous years in our clinic.
3.2. Microarray analysis
It was of interest to determine gene expression alterations in
banked fetal dermal skin cells (used in tissue engineering for burns
and wounds to date) and old dermal skin cells that have been
banked in the same manner to have a listing of potential gene fam-
ilies from fetal banked cells to compare to old skin cells and other
gene proﬁling studies. To identify differentially expressed genes in
banked fetal dermal skin cells, we used cDNA microarray contain-
ing approximately 12,500 sequences (U95A human genome chip,
Affymetrix UK, High Wycombe). Three arrays were hybridized for
banked fetal skin cells and banked old skin cells each. When com-
paring banked fetal dermal skin cells to banked old ﬁbroblasts with
our conditions, 116 genes changed by 1.5-fold log or more. Be-
tween those genes 54 were up-regulated in fetal cells and 62 were
down-regulated. Gene Ontology of important differentially ex-
pressed genes was annotated following the criteria of the DAVID
database (http://david.abcc.ncifcrf.gov/) for annotation, visualiza-
tion, and integrated discovery) (Dennis et al., 2003). Gene ontolo-
gies included apoptosis, cell adhesion, cell-cell signaling,
extracellular matrix, transcription factor, cytokine activity and im-
mune response. Many of the genes analyzed could be involved in
multiple cellular processes so they have been placed in a category
for their best representation. In Table 2, an exhaustive listing of all
signiﬁcantly different regulated genes between Banked Fetal Cells
and Banked Old Cells are presented. The majority of genes which
are up-regulated in banked fetal dermal skin cells are within cell
adhesion and extracellular matrix, (Table 3). The gene list was also
confronted with the KEGG database for analysis of signaling path-
ways. Of the 116 genes, 75 were not included in the data base and
Table 2
Regulated genes in fetal banked cells compared to old banked cells.
Entrez gene ID Gene symbol Gene name Fold increase (expressed in log2)
4232 MEST Mesoderm speciﬁc transcript homolog 4.598
2202 EFEMP-1 EGF-containing ﬁbulin-like extracellular matrix protein 1 4.041
5947 RBP1 Retinol binding protein 1, cellular 3.913
3875 KRT18 Keratin 18 3.533
1191 CLU Clusterin 3.511
5740 PTGIS Prostaglandin I2 (Prostacyclin) Synthase 3.209
5764 PTN Pleiotrophin (Neurite growth-promoting factor 1) 3.050
55816 DOK5 Docking protein 5 2.938
10924 SMPDL3A Sphingomyelin phosphodiesterase, acid-like 3A 2.833
894 CCND2 Cyclin D2 2.762
11341 SCRG1 Scrapie responsive protein 1 2.718
59 ACTA2 Actin, Alpha 2, Smooth muscle, Aorta 2.714
10234 LRRC17 Leucine rich repeat containing 17 2.676
7052 TGM2 Transglutaminase 2 2.657
4192 MDK Midkine (Neurite growth-promoting factor 2) 2.579
4781 NFIB Nuclear factor I/B 2.508
1264 CNN1 Calponin 1, Basic, Smooth muscle 2.490
2331 FMOD Fibromodulin 2.457
8324 FZD7 Frizzled homolog 7 2.405
23089 PEG10 Paternally expressed 10 2.365
2149 F2R Coagulation factor II (Thrombin) receptor 2.345
4628 MYH10 Myosin, Heavy polypeptide 10, Non-muscle 2.326
6422 SFRP1 Secreted frizzled-related protein 1 2.226
114882 OSBPL8 Oxysterol binding protein-like 8 2.164
10643 IGF2BP3 Insulin-like growth factor 2 mrna binding protein 3 2.143
8492 PRSS12 Protease, Serine, 12 (Neurotrypsin, Motopsin) 2.124
1909 EDNRA Endothelin receptor type A 2.095
65108 MARCKSL1 Marcks-like 1 2.068
1000 CDH2 Cadherin 2, Type 1, N-cadherin 2.038
2201 FBN2 Fibrillin 2 2.034
2239 GPC4 Glypican 4 2.034
2719 GPC3 Glypican 3 2.021
23705 IGSF4 Immunoglobulin superfamily, member 4 2.012
7472 WNT2 Wingless-type MMTV integration site family member 2 1.961
22836 RHOBTB3 Rho-related btb domain containing 3 1.881
9249 DHRS3 Dehydrogenase/reductase (SDR family) member 3 1.855
10962 MLLT11 Myeloid/lymphoid or mixed-lineage leukemia 1.795
5179 PENK Proenkephalin 1.782
1466 CSRP2 Cysteine and glycine-rich protein 2 1.741
586 BCAT1 Branched chain aminotransferase 1, cytosolic 1.736
22795 NID2 Nidogen 2 (Osteonidogen) 1.733
5360 PLTP Phospholipid transfer protein 1.683
23157 SEPT 6 Septin 6 1.656
23231 KIAA0746 KIAA0746 Protein 1.651
126393 HSPB6 Heat shock protein, alpha-crystallin-related, b6 1.645
1462 CSPG2 Chondroitin sulfate proteoglycan 2 (versican) 1.626
1028 CDKN1C Cyclin-dependent kinase inhibitor 1c (p57, kip2) 1.596
347733 TUBB2B Tubulin, beta 2B 1.575
9843 HEPH Hephaestin 1.570
7373 COL14A1 Collagen, type xiv, alpha 1 (undulin) 1.559
9865 KIAA0644 KIAA0644 gene product 1.550
10154 PLXNC1 Plexin C1 1.546
5157 PDGFRL Platelet-derived growth factor receptor-like 1.525
5997 RGS2 Regulator of g-protein signalling 2, 24KDA 1.513
10403 KNTC2 Kinetochore associated 2 1.507
1846 DUSP4 Dual speciﬁcity phosphatase 4 1.521
25945 PVRL3 Poliovirus receptor-related 3 1.536
1474 CST6 Cystatin E/M 1.542
202 AIM1 Absent in melanoma 1 1.549
9975 NR1D2 Nuclear receptor sub-family 1, group d, member 2 1.551
3600 IL15 Interleukin 15 1.577
4312 MMP1 Matrix metallopeptidase 1 (interstitial collagenase) 1.626
891 CCNB1 Cyclin B1 1.626
4907 NT5E 5’-Nucleotidase, ECTO (CD73) 1.627
133 ADM Adrenomedullin 1.654
2922 GRP Gastrin-releasing peptide 1.679
9123 SLC16A3 Solute carrier family 16, member 3 1.680
4603 MYBL1 V-MYB myeloblastosis viral oncogene homolog like 1 1.699
2199 FBLN2 Fibulin 2 1.704
1346 COX7A1 Cytochrome c oxidase subunit viia polypeptide 1 (muscle) 1.704
358 AQP1 Aquaporin 1 1.725
22885 ABLIM3 Actin binding lim protein family, member 3 1.782
960 CD44 CD44 antigen (indian blood group) 1.821
1410 CRYAB Crystallin, alpha B 1.824
(continued on next page)
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Table 2 (continued)
Entrez gene ID Gene symbol Gene name Fold increase (expressed in log2)
5420 PODXL Podocalyxin-like 1.830
1805 DPT Dermatopontin 1.841
9411 ARHGAP29 RHO gtpase activating protein 29 1.863
490 ATP2B1 ATPASE, CA++ transporting, plasma membrane 1 1.880
7035 TFPI Tissue factor pathway inhibitor 1.884
1033 CDKN3 Cyclin-dependent kinase inhibitor 3 1.885
857 CAV1 Caveolin 1, caveolae protein, 22KDA 1.921
347 APOD Apolipoprotein D 1.931
11098 PRSS23 Protease, serine, 23 1.976
25976 TIPARP Tcdd-inducible poly(ADP-RIBOSE) polymerase 1.979
1012 CDH13 Cadherin 13, H-cadheriN 1.987
1842 ECM2 Extracellular matrix protein 2 2.004
858 CAV2 Caveolin 2 2.025
8781 PSPHL Phosphoserine phosphatase-like 2.028
3134 HLA-F Major histocompatibility complex, class I, F 2.043
3490 IGFBP7 Insulin-like growth factor binding protein 7 2.062
8714 ABCC3 ATP-binding cassette, sub-family C 2.080
9404 LPXN Leupaxin 2.102
3037 HAS2 Hyaluronan synthase 2 2.147
4223 MEOX2 Mesenchyme homeobox 2 2.156
4885 NPTX2 Neuronal pentraxin ii 2.162
290 ANPEP Alanyl aminopeptidase 2.242
10974 C10orf116 Chromosome 10 open reading frame 116 2.270
26872 STEAP1 Six transmembrane epithelial antigen of the prostate 1 2.284
3115 HLA-DPB1 Major histocompatibility complex, class ii, dp beta 1 2.331
1728 NQO1 Nad(P)H dehydrogenase, quinone 1 2.336
9023 CH25H Cholesterol 25-hydroxylase 2.392
1396 CRIP1 Cysteine-rich protein 1 (intestinal) 2.421
11075 STMN2 Stathmin-like 2 2.433
5678 PSG9 Pregnancy speciﬁc beta-1-glycoprotein 9 2.569
5730 PTGDS Prostaglandin d2 synthase 21kda (brain) 2.620
8839 WISP2 Wnt1 inducible signaling pathway protein 2 2.825
25907 RIS1 RAS-induced senescence 1 2.848
8644 AKR1C3 ALDO-keto reductase family 1, member C3 2.976
4314 MMP3 Matrix metallopeptidase 3 (stromelysin 1, progelatinase) 3.130
131578 LRRC15 Leucine rich repeat containing 15 3.163
9976 CLEC2B C-type lectin domain family 2, member B 3.258
6275 S100A4 S100 calcium binding protein A4 3.458
7545 ZIC1 ZIC family member 1 4.051
3625 INHBB Inhibin, beta b 4.292
1311 COMP Cartilage oligomeric matrix protein 4.665
4982 TNFRSF11B Tumor necrosis factor receptor superfamily, member 11B 4.712
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only 1.76 genes were found to be included related to allograft
rejection, focal adhesion, TGF-b signaling pathway and cytokine-
cytokine receptor interaction. As there were very few genes for
any one pathway, it was difﬁcult to interpret the implication.
3.3. Gene expression analysis by real time PCR
RT–PCR was used to verify ﬁndings in the gene microarray
expression analysis of eight up-regulated and four down-regulated
selected genes. Gene expression was assessed relative to the con-
trol gene b-Actin in the cells of the microarray analysis. Mean val-
ues for the relative expression of selected genes and magnitudes of
upward or downward changes detected by RT–PCR are shown in
Table 4, as well as the fold differences obtained in the microarray
study. The expression levels of these genes were consistent with
the two techniques.
4. Discussion
In the clinical setting, we have seen practical advantages of fetal
cell therapy applied to preliminary patients with chronic wounds
(Ramelet et al., 2001). The cells are able to exert promoting effects
on adhesion, proliferation and migration of existing cells as the re-
paired wounds tend to heal gradually and the skin is much less
atrophic. Also, the pain alleviation following fetal construct appli-
cation was universal. In other studies using other autologous andallogenous grafting techniques (Khachemoune et al., 2002) allevia-
tion of pain was reported after several applications or days when
closer to healing was seen whereas in all of our patients it was seen
after application of the ﬁrst fetal construct. Obvious practical
advantages of the fetal skin construct technique are that it is
non-invasive and therefore surgical facilities are not necessary.
The method is easily applied in an ambulatory manor and the cells
are available right away instead of 4–6 weeks with traditional
auto-graft techniques. Similar to what we have seen in severe
burns, fetal skin constructs are showing promising results also
for chronic wound management and promoting an increased qual-
ity-of-life for these patients. Leg ulcers are multifactor in cause and
associated inﬂammation, ﬁbrosis and pain make the recalcitrant
ulcer difﬁcult to manage. There are also differences between males
and females as it is well accepted that hormones have a major im-
pact on regulation of wound repair and it has been further shown
that estrogen can inhibit local inﬂammatory responses by down-
regulation of macrophage inhibitory factor and thus improved tis-
sue repair seen (Ashcroft et al., 2003; Gulliver et al., in press).
Treatment of venous leg ulcers requires commitment and cooper-
ation between the patient and the care provider. It is important to
identify health-related quality-of-life factors (i.e. pain, itching, loss
of sleep, functional limitations) as many patients feel that related
symptoms are overlooked by doctors and thus can delay overall
healing (Chaby et al., 2006; Kahn et al., 2004). The impact of this
and other complications of venous leg ulcers on overall health
and quality-of-life is only beginning to be appreciated. New biolog-
Table 3
Microarray analysis sumary of signiﬁcantly different genes: fetal vs old.
Gene Ontology Number of genes differentially expressed (>1.5-fold) Up-regulated in fetal cells Percent up-regulated genes in fetal cells (%)
Total 116 54 47
Apoptosis 5 4 80
Cell adhesion 13 5 38
Cell–cell signaling 25 9 28
Extracellular matrix 15 9 60
Transcription factor 5 1 20
Cytokine activity 5 2 40
Immune response 4 0 0
Entrez gene ID Gene symbol Gene name Fold increase
Cell–cell signaling
5947 RBP1 Retinol binding protein 1, cellular 3.913
4781 NFIB Nuclear factor I/B 2.508
114882 OSBPL8 Oxysterol binding protein-like 8 2.164
10643 IGF2BP3 Insulin-like growth factor 2 mrna binding protein 3 2.143
8492 PRSS12 Protease, serine, 12 (neurotrypsin, motopsin) 2.124
9249 DHRS3 Dehydrogenase/reductase (sdr family) member 3 1.855
5179 PENK Proenkephalin 1.782
126393 HSPB6 Heat shock protein, alpha-crystallin-related, B6 1.645
347733 TUBB2B Tubulin, beta 2B 1.575
9975 NR1D2 Nuclear receptor subfamily 1, group D, member 2 1.551
3600 IL15 Interleukin 15 1.577
4312 MMP1 Matrix metallopeptidase 1 (interstitial collagenase) 1.626
4907 NT5E 50-nucleotidase, ECTO (CD73) 1.627
133 ADM Adrenomedullin 1.654
1346 COX7A1 Cytochrome C oxidase subunit viia polypeptide 1 (muscle) 1.704
1410 CRYAB Crystallin, alpha B 1.824
11098 PRSS23 Protease, serine, 23 1.976
25976 TIPARP TCDD-inducible poly(adp-ribose) polymerase 1.979
4223 MEOX2 Mesenchyme homeobox 2 2.156
4885 NPTX2 Neuronal pentraxin II 2.162
1728 NQO1 Nad(P)H dehydrogenase, quinone 1 2.336
5730 PTGDS Prostaglandin D2 synthase 21KDA (brain) 2.620
8644 AKR1C3 Aldo-keto reductase family 1, member C3 2.976
4314 MMP3 Matrix metallopeptidase 3 (stromelysin 1, progelatinase) 3.130
3625 INHBB Inhibin, beta B 4.292
Apoptosis
1191 CLU Clusterin 3.511
5740 PTGIS Prostaglandin i2 (prostacyclin) synthase 3.209
7052 TGM2 Transglutaminase 2 2.657
2149 F2R Coagulation factor ii (thrombin) receptor 2.345
4982 TNFRSF11B Tumor necrosis factor receptor superfamily, member 11B 4.712
Cell adhesion
1000 CDH2 Cadherin 2, type 1, n-cadherin 2.038
22795 NID2 Nidogen 2 (osteonidogen) 1.733
1462 CSPG2 Chondroitin sulfate proteoglycan 2 (versican) 1.626
7373 COL14A1 Collagen, type xiv, alpha 1 (undulin) 1.559
10154 PLXNC1 Plexin C1 1.546
960 CD44 CD44 antigen (Indian blood group) 1.821
5420 PODXL Podocalyxin-like 1.830
1805 DPT Dermatopontin 1.841
1012 CDH13 Cadherin 13, H-cadherin 1.987
1842 ECM2 Extracellular matrix protein 2 2.004
9404 LPXN Leupaxin 2.102
8839 WISP2 Wnt1 inducible signaling pathway protein 2 2.825
1311 COMP Cartilage oligomeric matrix protein 4.665
Extracellular matrix
2202 EFEMP-1 EGF-containing ﬁbulin-like extracellular matrix protein 1 4.041
7052 TGM2 Transglutaminase 2 2.657
2331 FMOD Fibromodulin 2.457
2201 FBN2 Fibrillin 2 (congenital contractural arachnodactyly) 2.034
2239 GPC4 Glypican 4 2.034
2719 GPC3 Glypican 3 2.021
22795 NID2 Nidogen 2 (osteonidogen) 1.733
1462 CSPG2 Chondroitin sulfate proteoglycan 2 (versican) 1.626
7373 COL14A1 Collagen, type xiv, alpha 1 (undulin) 1.559
4312 MMP1 Matrix metallopeptidase 1 (interstitial collagenase) 1.626
2199 FBLN2 Fibulin 2 1.704
1805 DPT Dermatopontin 1.841
1842 ECM2 Extracellular matrix protein 2 2.004
4314 MMP3 Matrix metallopeptidase 3 (stromelysin 1, progelatinase) 3.130
1311 COMP Cartilage oligomeric matrix protein 4.665
(continued on next page)
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Table 3 (continued)
Entrez gene ID Gene symbol Gene name Fold increase
Transcription factor
11336 NFIB Nuclear factor I/B 2.508
5760 NR1D2 Nuclear receptor subfamily 1, group D, member 2 1.551
673 MYBL1 V-MYB myeloblastosis viral oncogene homolog-like1 1.699
10496 MEOX2 Mesenchyme homeobox 2 2.156
Immune response
3600 IL15 Interleukin 15 1.577
3134 HLA-F Major histocompatibility complex, class I, F 2.043
3115 HLA-DPB1 Major histocompatibility complex, class II, DP beta 1 2.331
1396 CRIP1 Cysteine-rich protein 1 (intestinal) 2.421
9976 CLEC2B C-type lectin domain family 2, member B 3.258
Cytokine activity
5764 PTN Pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1) 3.050
4192 MDK Midkine (neurite growth-promoting factor 2) 2.579
3600 IL15 Interleukin 15 1.577
3625 INHBB Inhibin, beta b (activin ab beta polypeptide) 4.292
4982 TNFRSF11B Tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) 4.712
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can be assured. Nevertheless, a search for improvement of wound
healing therapies which can improve inﬂammation, pain manage-
ment and long-term closure is necessary for patient management
and their quality-of-life. Cell therapies and tissue engineering are
showing great promise in wound management. The cell choice is
therefore an important factor for simplifying the overall technique
and bringing therapy rapidly to the patient.
The precise mechanisms of efﬁcient wound healing remain un-
known despite the great increase in knowledge gained over the
past decade although fetal wound repair is a tightly regulated pro-
cess involving many cellular mediators. Chen et al. (2007) have
proposed that understanding the ‘‘blueprint of fetal skin repair”
might allow the manipulation of adult wound healing in order to
decrease scarring and ﬁbrosis. There are indeed many genes that
are signiﬁcantly different in the ‘‘fetal skin blueprint” when com-
pared to older skin that we have elucidated herein with banked fe-
tal and old dermal skin cells. These factors taken together and
presented in a cellular therapy seem to be an interesting approach
for chronic wounds.
We have seen major differences in gene families of banked fetal
dermal skin cells compared to old skin cells banked in the same
manner. Proﬁles that are predominant are in the families of genes
in cell adhesion and extracellular matrix, cell-cell signaling and im-
mune response conﬁrmed that our molecular data obtained byTable 4
Comparison of real time pcr to microarray analysis.
Relative gene expression MA Relative gene expression real time
(-ddcT)
Gene symbol
RBP1 3.91 7.35 ± 0.97
PTN 3.05 0.12 ± 0.36
MDK 2.57 1.9 ± 0.29
FMOD 2.45 2.86 ± 0.89
CDKN1C 1.59 4.59 ± 0.29
GDF10 0.25 1.45 ± 0.24
BMP6 0.43 2.21 ± 0.47
MMP14 0.63 1.64 ± 0.53
MMP1 1.62 1.41 ± 0.19
DPT 1.81 3.82 ± 0.26
HLA-DPB1 2.33 16.95 ± 1.82
MMP3 3.13 4.36 ± 0.59
INBHH 4.29 5.70 ± 0.14
TNFRSF11B 4.71 6.73 ± 0.24microarray were consistent with the published biochemical and
clinical ﬁndings related to efﬁcient fetal tissue repair.
In our microarray data, signiﬁcant increases were seen in matrix
proteins such as ﬁbromodulin (FMOD) and collagens compared to
old cells and these data correspond to the literature (Mast et al.,
1993; Hallock et al., 1993; Soo et al., 2000, 2002). FMOD was also
signiﬁcantly higher in the RT–PCR which was one of the random
probes selected for conﬁrmation of the microarray data. Genes
above and below the established curve from our statistical analysis
were chosen for this conformational purpose only. The most signif-
icantly expressed gene in the microarray data, EFEMP-1 or Fibulin
3 (FPLN-3) is homologous to FBLN-5 and are widely expressed ECM
proteins known to regulate cell proliferation and have also been
shown to antagonize angiogenesis. FBLN-5 has been shown to pro-
mote wound healing in vivo using a retroviral gene transfer to der-
mal wounds of rabbits showing 50% net increase of newly formed
granulation tissue and wound closure (Lee et al., 2004; Albig et al.,
2006; Soo et al., 2000). Microarray analysis has also shown the
importance of ECM glypicans which are proteins that can bind a
multitude of GF and ECM molecules which are implicated in signal
transduction cascaded that most likely regulate cell proliferation.
Glypicans activate or determine activities of morphogens and GF
such as FGF, BMPs and IGFs (Berry et al., 1998; De Cat and David,
2001; Hwang et al., 2001). We have seen that glycipans are up-reg-
ulated in fetal dermal skin cells (microarray data, GPC4 and GPC3
with 2.02 and 2.03 up-regulated, respectively) and in another re-
cent study by Lener et al. (2006) they had seen the same effect with
down-regulation of glycipans in aged skin. Many genes in the ECM
family can therefore interact with other gene families to regulate
cell growth, angiogenesis and migration. Migration is an important
ﬁbroblast response following tissue injury and is crucial to the re-
pair process. Fetal ﬁbroblasts possess more rapid intrinsic rates of
migration than that seen in adult skin ﬁbroblasts (Sandulache
et al., 2005; Sandulache et al., 2007).
Cell-cell signaling genes are related to cell growth characteris-
tics, differentiation and development of tissues and therefore
important for fetal dermal skin cells. In the microarray data, Reti-
nol binding Protein 1 (RBP1, gene encoding the carrier protein
for transport of vitamin A) which is necessary for growth and dif-
ferentiation of epithelial tissues was 3.9-fold increased in fetal der-
mal skin cells and conﬁrmation with RT–PCR at 6.45-fold higher
expression. Others such as Tubulin beta 2B (up-regulated at 1.58)
have been shown to be highly present in fetal brain development
(Nakamura et al. 2003).
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many cytokines, growth factors and their receptors (Constant
et al., 1997; Peled et al., 2001; Werner and Grose, 2003; Yang
et al., 2003) and it is suggested that efﬁcient wound healing in fetal
skin at early gestation is a result of the unique cytokine or growth
factor proﬁle. Of these, transforming growth factors-beta (TGF-b)
has been most widely studied and there are three highly homolo-
gous TGF-b isoforms known in humans: b1, b2 and b3. Published
studies have shown that it is the relative proportion of TGF-b iso-
forms, and not the absolute concentration of any one isoform
which determines the wound repair outcome; however, other
studies question the efﬁcacy of different isoforms (TGF-b3) in
wound healing (Sullivan et al., 1993; Vooijs et al., 2004; Wu
et al., 1997; Krummel et al., 1988; Lin et al, 1995) and we have
not seen a preponderant expression of these isoforms except for
TGF-b2 with 6-fold up-regulation in fetal cells in a previous study
analysis with RT–PCR (Hirt-Burri et al., 2008). This suggests that
factors other than TGF-b may also be important in efﬁcient repair.
In our microarray data, TGF-b superfamily genes such as Inhibin
(INHBB) and Cartilage oligomeric matrix protein (COMP) were sig-
niﬁcantly different in fetal dermal skin cells (INHBB, microarray
with 4.292; COMP, microarray with 4.665). Also, known to
modulate TGF-b activity, ECM constituents such as ﬁbromodulin
or decorin are expressed as a function of gestation age in fetal skin
(Beanes et al., 2001). This supports the hypothesis that differential
expression of TGF-b isoforms and TGF-b activity modulators, rather
than the mere presence or absence of TGF-b has a role in the reg-
ulation of efﬁcient repair.
An increased stimulus for angiogenesis and vascular permeabil-
ity may assist the rapid healing of wounds. Studies have shown
evidence for the importance of angiogenesis in wound repair.
Pleiotropin (PTN), a cytokine inducing heparin-binding/differentia-
tion, is certain to have a major role in angiogenesis in wound heal-
ing and can induce formation of functional neovaculature in vivo.
Midkine (MDK), which has 50% amino acid sequence identity and
striking domain homology to that of PTN are the two members
of the PTN/MDK developmental gene family (Christman et al.,
2005). Both PTN andMDK were shown to be signiﬁcantly increased
in fetal compared to adult skin with fold increase of 3.05 and 2.57,
respectively.
Not unexpected, genes involved in immune response were all
down-regulated in fetal dermal skin cells with ﬁve such genes
within the microarray. Among these genes highly implicated in
allograft rejection, include transplantation antigen Major Histo-
compatibility Complex of Class I (HLA-F, microarray with 2.043)
and Class II (HLA-DPB1, microarray with 2.331).
In all, fetal skin constructs show promise for treatment of acute
and chronic wounds as banked cells can be thoroughly screened for
unwanted virus and pathogen. Multiple treatments with fetal cell
constructs in an out-patient setting were well tolerated and posi-
tive effects of anti-inﬂammatory and anti-pain were evident.
Expression proﬁling of banked fetal dermal skin cells compared
to aged dermal skin cells has provided biological grouping of
important gene families implicated in the mechanism of wound re-
pair. Indeed, individual growth factors (TGF-b2, TGF-b3, IL-10,
PDGF) have been shown in the clinic to help in different aspects
of overall wound healing but it is a very complex process (Adzick
and Lorenz, 1994). Most likely, many factors taken together are
necessary for complete wound closure which could indeed be of-
fered by a cell-based therapy for chronic wound management.
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